Status:
NOT_YET_RECRUITING
Adequate Hydration and Health Outcomes
Lead Sponsor:
Arizona State University
Conditions:
Dehydration
Dehydration (Physiology)
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
Cardiovascular diseases (CVD) are the leading cause of death in middle- and high-income countries, according to data from the World Health Organization (WHO). Epidemiological studies have associated l...
Detailed Description
Protocol Subjects will first come into the lab for a screening visit (approximately 1 hour). In this visit, they will learn more about the study, provide written informed consent (if they choose to p...
Eligibility Criteria
Inclusion
- BMI 18.5-24.9 or 30.0-39.9 kg/m2
- HbA1c ≤7%
- Age 20-65 y
- available for 8 consecutive weeks same day and time
Exclusion
- Diabetes
- HbA1c \>7% BMI ≤18.5, BMI of 25 to \<30, or ≥ 40 kg/m2
- night shifting work
- losing or gaining weight during the last 2 months (\>5 lbs. fluctuation)
- thyroid medication
- bariatric surgery
- Habitual strenuous exercise (\>120 min/week) Strenuous exercise is defined as activities that take hard physical effort and make you breathe much harder than normal.
- Construction and other workers that spend signifant portion of their work day outdoors
- Commuting by bicycle
- Eating disorders
- Use of aspirin during the duration of the study
- Cancer
- Renal disease (including kidney stones or recurrent urinary track infections
- Hepatic disease
- Cardiac conditions
- Current infection requiring medication
- Chronic, contagious, infectious diseases such as tuberculosis, Hepatitis A, B, C, or HIV
- Medication that could affect appetite or body weight regulation
- GLP1-RA medication
- Anti-depressent SSRI medication
- Testosterone replacement therapy
- Participating in another study at the same time
- Unable to abstain from alcohol during the study
- Unable to limit caffeinated beverage intake to 1 cup per day
- Donated blood during the past two months
- Uneasibly acessable veins
- Does not have smart phone
Key Trial Info
Start Date :
September 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT07179107
Start Date
September 25 2025
End Date
December 31 2028
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
850 Phoenix Bioscience Core
Phoenix, Arizona, United States, 85004